Carter Eric G 4

What Happened

• Eric G. Carter, a director of AEON Biopharma, received a grant of 222,684 restricted stock units (RSUs) on June 17, 2026. The filing reports the award as an acquisition (transaction code A) at $0.00 per unit — no cash was paid. The RSUs do not represent immediately tradable shares until they vest.

Key Details

• Transaction date: 2026-06-17; filing date (Form 4): 2026-06-22.
• Amount: 222,684 RSUs granted; reported price per unit: $0.00.
• Shares owned after the transaction: not disclosed in the filing.
• Footnote: RSUs vest in full on the earlier of (i) the one-year anniversary of the grant (June 17, 2027) or (ii) the date of the 2027 annual meeting of stockholders, subject to continued service through the vesting date.
• Timeliness: The Form 4 was filed five calendar days after the grant (appears to exceed the typical two-business-day Form 4 reporting window).

Context

• RSU grants are compensation awards, not open-market purchases or sales; they become shares only upon vesting and are commonly used to align insiders with shareholder interests. Such awards do not necessarily signal the insider’s near-term trading intent. Taxes and any withholding at vesting can affect the number of shares ultimately issued.